Morocco Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Morocco Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Morocco Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: We hold an optimistic outlook for the Moroccan pharmaceutical market despite the economic slowdown over 2016. We expect the government ' s increasing efforts to improve healthcare coverage coupled with the country ' s growing non-communicable disease burden will drive the demand for medicines in long-term. A major downside risk to our forecast is the uncertainty surrounding drug prices as a result of price cuts and increased taxation on medicines in recent years, which will negatively impact the attractiveness of the market to multinational drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: MAD13.39bn (USD1.40bn) in 2015 to MAD14.34bn (USD1.46bn) in 2016; +7.1% in local currency terms and +4.0% in US dollar terms. Forecast inline with last quarter .

  • Healthcare: MAD59.15bn (USD6.19bn) in 2015 to MAD62.83bn (USD6.38bn) in 2016; +6.2% in local currency terms and +3.1% in US dollar terms. Forecast revised downwards from last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Morocco 2014-2020)
2014 2015e 2016f 2017f 2018f 2019f 2020f
e/f = BMI estimate/forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.489 1.401 1.456 1.619 1.794 1.951 2.082
Pharmaceutical sales, % of GDP 1.36 1.37 1.38 1.39 1.40 1.40 1.41
Pharmaceutical sales, % of health expenditure 22.5 22.6 22.8 23.0 23.2 23.3 23.5
Health spending, USDbn 6.609 6.190 6.382 7.038 7.744 8.361 8.864

Risk/Reward Index

Morocco is viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region. In our Q216 proprietary Pharmaceutical Risk/Reward Index (RRI) table, Morocco is ranked as the 12th most attractive market in the region out of the 31 countries assessed, scoring 45.5 out of 100 (43.0 in Q116). The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Latest Updates

  • In February 2016, Human Rights Watch reported that more than 62,000 Moroccans need palliative care every year and that despite government efforts to improve end-of-life care, only two public hospitals (located in Casablanca and Rabat) are capable of delivering this health service.

  • In January 2016, the Moroccan Health Ministry announced it has taken preventative measures against the possible spread of the Zika virus to the country and that no cases have yet been reported.

  • In November 2015, the Moroccan Association of the pharmaceutical industry (AMIP) and Morocco Export visited Ethiopian capital, Addis Ababa to explore market access procedures and export opportunities in Ethiopia.

  • In November 2015, Private equity firm Abraaj Group acquired a majority stake in the Centre de Traitement Al Kindy (Al Kindy) in Casablanca, as well as in the Clinique Specialisee Menara (Menara) in Marrakech, which together, form the largest private integrated network of imaging diagnostics and cancer treatment centres in Morocco.

BMI Economic View

Morocco's economic growth will slow down significantly over 2016, as agricultural production collapses on the back of a drought. On the upside, exports will continue to outperform, and investment will remain elevated, as the country pushes forward with its plan to become a regional exporting hub between Europe and Africa. As a result, we forecast growth to reach only 2.0% over 2016, compared to 4.4% in 2015.

BMI Political View

The diplomatic crisis between Morocco and the European Union related to the Western Sahara will subside rapidly, as both parties will overlook the issue to work towards deeper political and economic cooperation. As a result, Morocco will continue to increase its diplomatic importance in the MENA region, and remain a central ally for the EU.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Morocco 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2012-2020)
13
Healthcare Market Forecast
14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020)
16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2012-2020)
16
Prescription Drug Market Forecast
17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020)
19
Patented Drug Market Forecast
20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2012-2020)
26
OTC Drug Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2012-2020)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2014-2020)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2014-2020)
33
Pharmaceuticals & Healthcare Risk/Reward Index
34
Middle East and Africa Risk/Reward Index - Q2 2016
34
Morocco Risk/ Reward Index
41
Rewards
41
Risks
42
Regulatory Review
44
Intellectual Property Regime
45
Pricing Regime
45
Reimbursement Regime
48
Market Overview
51
Epidemiology
51
Healthcare Sector
54
Table: Healthcare Resources (Morocco 2010-2015)
58
Table: Healthcare Personnel (Morocco 2010-2015)
59
Table: Healthcare Activity (Morocco 2010-2015)
59
Healthcare Insurance
59
Recent Health Insurance Developments
61
Research & Development
64
Clinical Trials
65
Competitive Landscape
66
Pharmaceutical Industry
66
Table: Morocco's Select Pharmaceutical Industry Indicators
66
Table: Members Of MIS, 2011
67
Table: Members Of AMIP, 2011
68
Domestic Pharmaceutical sector
68
Foreign Pharmaceutical Companies
69
Table: Multinational Market Activity
72
Pharmaceutical Wholesale
72
Pharmaceutical Retail
73
Company Profile
75
GlaxoSmithKline
75
Laprophan
77
Pfizer
80
Sanofi
83
Sothema
87
Demographic Forecast
90
Demographic Outlook
90
Table: Population Headline Indicators (Morocco 1990-2025)
91
Table: Key Population Ratios (Morocco 1990-2025)
91
Table: Urban/Rural Population & Life Expectancy (Morocco 1990-2025)
92
Table: Population By Age Group (Morocco 1990-2025)
92
Table: Population By Age Group % (Morocco 1990-2025)
93
Glossary
95
Methodology
97
Pharmaceutical Expenditure Forecast Model
97
Healthcare Expenditure Forecast Model
97
Notes On Methodology
98
Risk/Reward Index Methodology
99
Index Overview
100
Table: Pharmaceutical Risk/Reward Index Indicators
100
Indicator Weightings
101

The Morocco Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Morocco pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Morocco, to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.